retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide (LY3437943): Mechanism of Action

Williams, Aikaterini Eleftheriadou, Uazman Alam, Daniel J

While some may experience mild bloating as the gut adjusts, many experience little to no side effects.* Next-Generation Gut Support - Unlike many common probiotics, Akkermansia doesnt just populate the gut - it helps strengthen the very environment your microbiome depends on

A common druggable defect in regulatory T cells from patients with autoimmunity

Discontinuation: If symptoms are severe, persistent, or suggestive of hypersensitivity, discontinuing the medication may be necessary

These cases allege that the manufacturers promoted the medications as revolutionary weight-loss treatments while concealing severe risks such as gastroparesis, ileus, and bowel obstruction

For peptides that target specific areas, like BPC-157 for tendon injuries , some protocols suggest injecting as close to the affected area as practical